MDM2 inhibition: an important step forward in cancer therapy
Author:
Funder
Roche
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Link
http://www.nature.com/articles/s41375-020-0949-z.pdf
Reference100 articles.
1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.
2. Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem. 2016;85:375–404.
3. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13:23–31.
4. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9:749–58.
5. Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol. 2018;15:13–30.
Cited by 257 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. MDM2 inhibitors in cancer immunotherapy: Current status and perspective;Genes & Diseases;2024-11
2. An efficient route for synthesis of spirocyclic cyclopentapyridines;Tetrahedron Letters;2024-10
3. Experimental and computational studies of novel amide analogues of ferulic acid as potential MDM2 inhibitors to retrieve p53 function;Journal of Molecular Structure;2024-10
4. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13
5. Platinum–Selenopeptide Interfaces in Support of High Fidelity Electrochemical Biomarker Quantification in Complex Biological Matrices;Analytical Chemistry;2024-09-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3